82 results
6-K
XTLB
X.T.L. Biopharmaceuticals Ltd.
15 Nov 23
Report of Foreign Private Issuer
10:29am
with a unique mechanism of action and clinical data on over 400 patients in three clinical studies. The drug has a favorable safety profile, is well … article in Lupus Science and Medicine journal titled “Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus
6-K
XTLB
X.T.L. Biopharmaceuticals Ltd.
10 Aug 23
Report of Foreign Private Issuer
9:30am
in three clinical studies. The drug has a favorable safety profile, is well tolerated by patients and has demonstrated efficacy in at least one … clinically meaningful endpoint. For more information, please see the peer reviewed article in Lupus Science and Medicine journal titled “Safety and efficacy
6-K
XTLB
X.T.L. Biopharmaceuticals Ltd.
16 May 23
Report of Foreign Private Issuer
11:00am
is a novel compound with a unique mechanism of action and clinical data on over 400 patients in three clinical studies. The drug has a favorable safety … the peer reviewed article in Lupus Science and Medicine journal titled “Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus
6-K
XTLB
X.T.L. Biopharmaceuticals Ltd.
29 Nov 22
Report of Foreign Private Issuer
11:16am
. The drug has a favorable safety profile, is well tolerated by patients and has demonstrated efficacy in at least one clinically meaningful endpoint … . For more information, please see the peer reviewed article in Lupus Science and Medicine journal titled “Safety and efficacy of hCDR1 (Edratide
6-K
p7q7oq x4
24 Aug 22
Condensed Interim Unaudited Consolidated Financial Statements
10:30am
6-K
a7kr4dz4hz2eiox
1 Jun 22
Report of Foreign Private Issuer
4:32pm
6-K
gbgmvucklwkvxytsgi5
24 Nov 21
Report of Foreign Private Issuer
10:29am
424B3
otx pjjm7
9 Jun 21
Prospectus supplement
8:06am
POS AM
ljn 7lulp6
2 Jun 21
Prospectus update (post-effective amendment)
1:44pm
6-K
d54q 8tz5a
19 May 21
Report of Foreign Private Issuer
11:39am
20-F/A
4za8vcnm2lb2 id7
19 May 21
Annual report (foreign) (amended)
11:30am
6-K
447 l9rqf2v5g
19 May 21
Report of Foreign Private Issuer
11:25am
6-K
y9qt4onx g6
12 Nov 20
Report of Foreign Private Issuer
9:59am
6-K
su12j
24 Aug 20
Report of Foreign Private Issuer
9:23am
6-K
xzqqw4 1vihvjthjksd
27 May 20
Report of Foreign Private Issuer
9:20am
6-K
7jnr68 o9tr
27 Nov 19
Current report (foreign)
12:28pm